文献速递血液净化与透析

维持性血透患者对mRNA-1273与BNT162b2新冠疫苗的体液与细胞免疫应答

Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients.
PubMed 文献 · Am J Kidney Dis · 2021-06-24

该前瞻性多中心队列研究纳入西班牙巴塞罗那3个透析中心的205例维持性透析患者,于2021年2月3日至4月4日接种mRNA-1273或BNT162b2疫苗。在175例基线血清阴性的接种患者中,97.7%产生体液和/或细胞应答,95.4%发生血清转换,62%受检者细胞免疫阳性;高龄和免疫抑制治疗与较低抗体水平相关。

要点

  • 维持性透析患者接种mRNA新冠疫苗后绝大多数产生体液和/或细胞免疫应答。
  • 高龄及免疫抑制治疗与较低的抗S1-RBD IgG水平相关。
  • 透析患者感染风险高、结局差,应优先接种新冠疫苗。

核心结论

  • 维持性透析的肾衰竭患者接种mRNA新冠疫苗后,高比例产生体液和细胞免疫应答。

研究设计与样本

  • 观察性前瞻性多中心队列研究,纳入西班牙巴塞罗那Hospital Clínic 3个透析单元的205例维持性透析患者,2021年2月3日至4月4日接种,随访至2021年4月23日。

主要发现

  • 175例基线血清阴性的接种患者中,97.7%产生应答(体液、细胞或两者兼有)。
  • 95.4%的患者发生血清转换。
  • 接受细胞免疫检测的患者中62%为阳性应答。
  • 高龄和免疫抑制治疗与较低的抗体水平相关。

关键数值与推荐

  • 血清转换定义为检测到针对SARS-CoV-2 S1刺突抗原受体结合域的IgG抗体(抗S1-RBD IgG)。
  • 细胞免疫应答定义为完成接种3周后检测到活化的CD4+T细胞。
  • 抗S1-RBD IgG水平报告上限为150 U/mL。

临床怎么用

  • 维持性透析患者应优先接种mRNA新冠疫苗以预防SARS-CoV-2感染。
  • 对高龄或接受免疫抑制治疗的患者,需关注其疫苗应答可能较低。

局限性

  • 疫苗由卫生当局强制接种。
  • 抗S1-RBD IgG水平仅报告至150 U/mL,细胞免疫应答为定性描述。
  • 抗体检测和细胞应答评估方法可能与既往发表的实验室方法不可比。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Patients with kidney failure who are receiving maintenance dialysis have a higher risk of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and worse clinical outcomes after coronavirus disease 2019 (COVID-19) than the general population. Therefore, immunization against SARS-CoV-2 with effective vaccines is an important component of health-maintenance strategies for these patients. This study evaluated the humoral and cellular responses to messenger RNA (mRNA) SARS-CoV-2 vaccines in this population. STUDY DESIGN: Observational prospective multicenter cohort study. SETTING & PARTICIPANTS: 205 patients treated at 3 dialysis units at the Hospital Clínic of Barcelona (Spain) were vaccinated from February 3 to April 4, 2021, and followed until April 23, 2021. EXPOSURE: Immunization with either the mRNA-1273 (Moderna) or BNT162b2 (Pfizer-BioNTech) SARS-CoV-2 mRNA vaccine. OUTCOME: Seroconversion, defined as the detection of IgG antibodies to the receptor-binding domain of the S1 spike antigen of SARS-CoV-2 (anti-S1-RBD IgG), and the identification of activated CD4+T cells 3 weeks after completing vaccination. Anti-S1-RBD IgG levels were also analyzed as a secondary outcome. ANALYTICAL APPROACH: Univariate and multivariable logistic and multiple linear regression models were used to evaluate the associations between vaccination and study outcomes. RESULTS: We found that 97.7% of 175 vaccinated patients who were seronegative at baseline developed a response (humoral, cellular, or both); 95.4% of these patients seroconverted, while 62% of those tested for cellular immunity had a positive response. Greater age and immunosuppressive treatment were associated with lower antibody levels. LIMITATIONS: Mandatory vaccine administration by health authorities. Anti-S1-RBD IgG levels were reported up to 150U/mL and cellular immune responses were characterized qualitatively. Antibody assay and cellular response assessment may not be comparable with previously published laboratory approaches. CONCLUSIONS: Immunization with mRNA vaccines generated a humoral and cellular immune response in a high proportion of patients with kidney failure receiving maintenance dialysis. These findings as well as the high risk of infection and poor clinical outcomes among these patients make their vaccination a health priority.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Broseta JJ, Rodríguez-Espinosa D, Rodríguez N, et al. Humoral and Cellular Responses to mRNA-1273 and BNT162b2 SARS-CoV-2 Vaccines Administered to Hemodialysis Patients. Am J Kidney Dis. 2021. PMID: 34174364. doi:10.1053/j.ajkd.2021.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。